Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Intrastromal Versus Subconjunctival Injection of Mesenchymal Stem/Stromal Cells for Promoting Corneal Repair Publisher Pubmed



Soleimani M1, 2 ; Mirshahi R3 ; Cheraqpour K2 ; Baharnoori SM1 ; Massoumi H1 ; Chow C4 ; Shahjahan S5 ; Momenaei B6 ; Ashraf MJ1 ; Koganti R1 ; Ghassemi M1 ; Anwar KN1 ; Jalilian E1 ; Djalilian AR1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, United States
  2. 2. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Eye Research Center, The Five Senses Health Institute, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States
  5. 5. Des Moines University, Des Moines, IA, United States
  6. 6. Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, PA, United States

Source: Ocular Surface Published:2023


Abstract

Purpose: Different approaches to delivery of mesenchymal stem/stromal cells (MSCs) for ameliorating corneal injuries have been investigated. This study was aimed to compare the efficacy of intrastromal and subconjunctival injection of human bone marrow-derived MSCs (hBM-MSCs) in a corneal epithelial injury model. Methods: Twenty-four C57BL/6J mice underwent total corneal and limbal epithelial debridement. Then, the mice were divided into three different groups: (1) intrastromal hBM-MSCs injection, (2) subconjunctival hBM-MSCs injection, and (3) injection of frozen medium as a control. Mice were monitored by slit lamp and underwent anterior segment optical coherence tomography (ASOCT). Following euthanasia, the corneas were further evaluated by histology and immunostaining. Results: hBM-MSC injection successfully healed epithelial defects regardless of the delivery route (P < 0.001). However, intrastromal injection was superior to subconjunctival injection in reducing defect area (P = 0.001). Intrastromal injection of hBM-MSCs also significantly reduced corneal opacity and neovascularization and improved ASOCT parameters compared to subconjunctival injection or no treatment (P < 0.001, P = 0.003, and P < 0.001, respectively). Although both of the treatment groups were positive for CK12 and had reduced levels of MUC5AC compared to the control, CK12 staining was stronger in the intrastromal group compared to the subconjunctival group. Also, persistency of MSCs was confirmed by in vivo (up to 2 weeks) and in vitro assessments (up to 4 weeks). Conclusions: Although the injection of hBM-MSC using both intrastromal and subconjunctival methods improve wound healing and reduce neovascularization and opacity, the intrastromal approach is superior in terms of corneal healing. © 2023